0001179110-21-001118.txt : 20210202 0001179110-21-001118.hdr.sgml : 20210202 20210202193556 ACCESSION NUMBER: 0001179110-21-001118 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210104 FILED AS OF DATE: 20210202 DATE AS OF CHANGE: 20210202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KANGO SUJAY CENTRAL INDEX KEY: 0001336503 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 21583557 MAIL ADDRESS: STREET 1: 1028 CHAMBERS COURT CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4/A 1 edgar.xml FORM 4/A - X0306 4/A 2021-01-04 2021-01-06 0 0001280600 ACCELERON PHARMA INC XLRN 0001336503 KANGO SUJAY 128 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2021-01-04 4 M 0 10000 40.61 A 13987 D Option to Purchase Common Stock 40.61 2021-01-04 4 M 0 10000 0 D 2028-03-01 Common Stock 10000 40000 D This Form 4 amendment is being filed to report the exercise of an option to purchase common stock that was inadvertently omitted from the original Form 4 filed on January 6, 2021. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reflects the holdings of the reporting person as of the date of the original Form 4 filed on January 6, 2021, taking into account the transactions set forth in such original Form 4 and the transaction set forth in this amendment. The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of February 12, 2018 and the remaining shares vest in equal quarterly installments over the following three years thereafter. /s/ Adam M. Veness, as attorney-in-fact for Sujay Kango 2021-02-02